医学部附属病院

研究キーワード

肝硬変 ,マウスモデル ,肝細胞癌 ,非アルコール性脂肪性肝疾患

研究分野

ライフサイエンス / 栄養学、健康科学 /
ライフサイエンス / 病態医化学 /
ライフサイエンス / 消化器内科学 / 肝臓病学

論文

Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma.

Na Qiang Junjie Ao Masato Nakamura Tetsuhiro Chiba Yuko Kusakabe Tatsuya Kaneko Akane Kurosugi Tadayoshi Kogure Yaojia Ma Jiaqi Zhang Keita Ogawa Motoyasu Kan Terunao Iwanaga Takafumi Sakuma Kengo Kanayama Hiroaki Kanzaki Ryuta Kojima Ryo Nakagawa Takayuki Kondo Shingo Nakamoto Ryosuke Muroyama Jun Kato Naoya Mimura Anqi Ma Jian Jin Naoya Kato

International immunopharmacology 118 110068-110068 2023年5月

Enhancer of zeste homolog 2 (EZH2), a core component of polycomb repressive component 2 is overexpressed in a variety of cancers and recognized as a therapeutic target molecule. However, EZH2 possesses immunomodulatory functions in the tumor micro...

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.

Sae Yumita Sadahisa Ogasawara Miyuki Nakagawa Susumu Maruta Tomomi Okubo Norio Itokawa Yotaro Iino Masamichi Obu Yuki Haga Atsuyoshi Seki Tadayoshi Kogure Takamasa Ishino Keita Ogawa Kisako Fujiwara Terunao Iwanaga Naoto Fujita Takafumi Sakuma Ryuta Kojima Hiroaki Kanzaki Keisuke Koroki Masanori Inoue Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Ei Itobayashi Masanori Atsukawa Yoshihiro Koma Ryosaku Azemoto Kenji Ito Hideaki Mizumoto Jun Kato Naoya Kato

BMC gastroenterology 23(1) 101-101 2023年3月 [査読有り]

BACKGROUND: Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to cla...

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.

Naoya Kanogawa Sadahisa Ogasawara Susumu Maruta Yotaro Iino Masamichi Obu Takamasa Ishino Keita Ogawa Sae Yumita Terunao Iwanaga Hidemi Unozawa Miyuki Nakagawa Kisako Fujiwara Takafumi Sakuma Naoto Fujita Ryuta Kojima Hiroaki Kanzaki Keisuke Koroki Kazufumi Kobayashi Masanori Inoue Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Ei Itobayashi Yoshihiro Koma Ryosaku Azemoto Jun Kato Naoya Kato

BMC gastroenterology 23(1) 70-70 2023年3月 [査読有り]

PURPOSE: Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in patie...

Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors.

Keita Ogawa Tetsuhiro Chiba Masato Nakamura Jun Arai Jiaqi Zhang Yaojia Ma N A Qiang Junjie Ao Sae Yumita Takamasa Ishino Motoyasu Kan Terunao Iwanaga Miyuki Nakagawa Kisako Fujiwara Takafumi Sakuma Hiroaki Kanzaki Keisuke Koroki Yuko Kusakabe Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Ryo Nakagawa Sadahisa Ogasawara Ryosuke Muroyama Shingo Nakamoto Tatsuo Kanda Hitoshi Maruyama Jun Kato Shoji Matsumoto Takayoshi Arai Shinichiro Motohashi Naoya Kato

Anticancer research 43(3) 1043-1052 2023年3月

BACKGROUND/AIM: MHC-class I-related chain A (MICA) functions as a ligand for natural killer group D, an activating receptor on natural killer (NK) cells, and its expression correlates with the carcinogenesis and progression of hepatocellular carci...

Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.

Terunao Iwanaga Tetsuhiro Chiba Masato Nakamura Tatsuya Kaneko Junjie Ao Na Qiang Yaojia Ma Jiaqi Zhang Tadayoshi Kogure Sae Yumita Takamasa Ishino Keita Ogawa Motoyasu Kan Miyuki Nakagawa Kisako Fujiwara Naoto Fujita Takafumi Sakuma Hiroaki Kanzaki Keisuke Koroki Yuko Kusakabe Masanori Inoue Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Ryo Nakagawa Sadahisa Ogasawara Shingo Nakamoto Ryosuke Muroyama Jun Kato Tatsuo Kanda Hitoshi Maruyama Naoya Mimura Takuya Honda Toshihiko Murayama Hiroyuki Nakamura Naoya Kato

Biochemical and biophysical research communications 642 192-200 2023年1月

Transforming growth factor (TGF)-β/Smad pathway is implicated in the pathogenesis of liver fibrosis, a condition characterized by excessive deposition of extracellular matrix (ECM) proteins such as collagen in response to chronic inflammation. It ...